Aclaris Therapeutics (ACRS) investor relations material

Executive summary

• Focused on developing novel small and large molecule candidates for immuno-inflammatory diseases, leveraging the KINect drug discovery platform and seeking strategic partnerships for development and commercialization.

• Achieved key clinical milestones, including positive Phase 1a results for ATI-052 and reaffirmed timelines for multiple upcoming clinical readouts in 2026.

• Key pipeline assets include bosakitug (anti-TSLP mAb), ATI-052 (bispecific anti-TSLP/IL-4Ra), modzatinib (ITK/JAK3 inhibitor), and ATI-9494 (ITK/TXK inhibitor), with multiple clinical trials ongoing or planned.

• Positioned for significant catalysts in the second half of 2026, including Phase 1b and Phase 2 trial results and new trial initiations.

Financial highlights

• Net loss for the six months ended June 30, 2026 was $41.3 million, compared to $30.5 million year-over-year.

• Total revenue for the six months ended June 30, 2026 was $3.6 million, up from $3.2 million year-over-year, driven by higher licensing revenue.

• Research and development expenses increased to $33.7 million for the first half of 2026, primarily due to ATI-052 and ATI-9494 development.

• General and administrative expenses rose to $12.8 million for the first half of 2026, mainly due to higher headcount, professional, legal, and personnel costs.

• Cash, cash equivalents, and marketable securities totaled $170.6 million as of June 30, 2026.

Outlook and guidance

• Existing cash, cash equivalents, and marketable securities are expected to fund operations for more than 12 months from the reporting date, with some guidance projecting runway through 2028, excluding additional financing.

• Top-line data from key clinical trials (bosakitug Phase 2, ATI-052 Phase 1b) expected in the second half and fourth quarter of 2026.

• Additional capital will be required to advance product candidates and support discovery efforts; potential sources include equity, partnerships, and milestone payments.